28th November 2016
Finding New Uses for ARGUS Technology in Age-Related Macular Degeneration
by Adam Hochron
As a retinal implant, the ARGUS II technology has shown early benefits for patients with retinitis pigmentosa. A new study from the United Kingdom is examining its benefits in patients with the dry form of age-related macular degeneration (AMD).
Paulo E. Stanga, MD, from the Manchester Royal Eye Hospital, discussed his work in this trial during the annual meeting of the American Academy of Ophthalmology in Chicago, IL. One of the biggest challenges, according to Stanga, for the five patients is balancing their residual peripheral vision with the central visual function which the device provides.